You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 108 No. 2, February 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  LABORATORY SCIENCES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (67)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Retinal Toxicity of Recombinant Tissue Plasminogen Activator in the Rabbit

Mark W. Johnson, MD; Karl R. Olsen, MD; Eleut Hernandez; W. David Irvine, MD; Robert N. Johnson, MD

Arch Ophthalmol. 1990;108(2):259-263.


Abstract

• We studied the dose-dependent retinal toxicity of the available commercial preparation of human recombinant tissue plasminogen activator in the normal rabbit eye. Tissue plasminogen activator was injected into the midvitreous cavity of albino rabbits in doses (per 100 µL) of 25, 50, 75, and 100 µg. Control eyes received 100 µL of balanced salt solution or tissue plasminogen activator vehicle. No evidence of a retinal toxic reaction was seen in eyes receiving 25 µg of tissue plasminogen activator. One of four eyes injected with 50 µg showed loss of photoreceptor cells by light microscopy. Severe retinal damage was seen by ophthalmoscopy, electroretinography, and light microscopy in three of four eyes receiving 75 µg of tissue plasminogen activator and in all eyes treated with 100 µg of tissue plasminogen activator or equivalent vehicle. These results suggest that the commercial recombinant tissue plasminogen activator formulation has a narrow margin of safety in nonvitrectomized eyes and that a component of the vehicle is the toxic factor.



Author Affiliations

From the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami (Fla) School of Medicine. Dr R. Johnson is now in private practice in San Francisco, Calif.


Footnotes

Accepted for publication September 18, 1989.

Read before the annual meeting of the Association for Research in Vision and Ophthalmology, Sarasota, Fla, May 3, 1989.

Reprint requests to Bascom Palmer Eye Institute, PO Box 016880, Miami, FL 33101 (Dr Olsen).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Toxic Effects of Recombinant Tissue Plasminogen Activator on Cultured Human Corneal Endothelial Cells
Yoeruek et al.
IOVS 2008;49:1392-1397.
ABSTRACT | FULL TEXT  

Pars plana vitrectomy with peripheral retinotomy after injection of preoperative intravitreal tissue plasminogen activator: a modified procedure to drain massive subretinal haemorrhage
Oshima et al.
Br J Ophthalmol 2007;91:193-198.
ABSTRACT | FULL TEXT  

Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion
Mahmoud et al.
Br J Ophthalmol 2006;90:911-915.
ABSTRACT | FULL TEXT  

A study of retinal penetration of intravitreal tenecteplase in pigs.
Kwan et al.
IOVS 2006;47:2662-2667.
ABSTRACT | FULL TEXT  

Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator.
Singh et al.
Br J Ophthalmol 2006;90:429-431.
ABSTRACT | FULL TEXT  

Intravitreal Injection of Tissue Plasminogen Activator: Four Considerations
Hesse and Johnson
Arch Ophthalmol 2001;119:456-457.
FULL TEXT  

Recombinant tissue plasminogen activator following paediatric cataract surgery
Mehta and Adams
Br J Ophthalmol 2000;84:983-986.
ABSTRACT | FULL TEXT  

Nonsurgical Management of Macular Hemorrhage Secondary to Retinal Artery Macroaneurysms
McCabe et al.
Arch Ophthalmol 2000;118:780-785.
ABSTRACT | FULL TEXT  

Retinal Toxicity of Commercial Intravitreal Tissue Plasminogen Activator Solution in Cat Eyes
Hrach et al.
Arch Ophthalmol 2000;118:659-663.
ABSTRACT | FULL TEXT  

Pneumatic Displacement of Subretinal Hemorrhage Without Tissue Plasminogen Activator
Ohji et al.
Arch Ophthalmol 1998;116:1326-1332.
ABSTRACT | FULL TEXT  

Tissue Plasminogen Activator and Staphylococcus epidermidis Endophthalmitis
Ryan and Mizener
Arch Ophthalmol 1993;111:1117-1122.
ABSTRACT  

Evaluation of a Commercial Recombinant Tissue-Type Plasminogen Activator Preparation in the Subretinal Space of the Cat
Benner et al.
Arch Ophthalmol 1991;109:1731-1736.
ABSTRACT  

Retinal Toxicity of Human Tissue Plasminogen Activator in Vitrectomized Rabbit Eyes
Irvine et al.
Arch Ophthalmol 1991;109:718-722.
ABSTRACT  

Intraocular Tissue Plasminogen Activator in a Rabbit Model of Traumatic Hyphema
Howard et al.
Arch Ophthalmol 1991;109:272-274.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.